Answers are grounded in this paper and cite their sources.
Colorectal cancer (CRC) often responds incompletely to immunotherapy because tumor cells display limited immunogenicity and are embedded in an immunosuppressive microenvironment. Here, we engineered CPAN, a hyaluronic acid‐modified celastrol‐platinum(IV) nanoprodrug, to sensitize tumors to programmed cell death protein 1 (PD‐1) blockade by linking ferroptosis with caspase‐independent pyroptosis. Following tumor‐oriented delivery, CPAN perturbed redox balance through peroxiredoxin 1 (PRDX1) inhibition, glutathione (GSH) depletion, glutathione peroxidase 4 (GPX4) reduction, and heme oxygenase 1 (HO‐1) upregulation, which together promoted ferrous iron (Fe 2 + )‐associated lipid peroxidation. The platinum(IV) moiety concurrently activated poly(ADP‐ribose) polymerase (PARP)/PARylation signaling. These lipid reactive oxygen species (ROS)‐ and PARylation‐dependent events drove oligomerization of full‐length gasdermin E (GSDME), producing caspase‐independent pyroptotic death. The resulting immunogenic cell death (ICD) was evidenced by adenosine triphosphate (ATP) release, calreticulin (CRT) exposure, high mobility group box 1 (HMGB1) translocation, and increased dendritic cell (DC) maturation. In CT26 tumor‐bearing mice, CPAN restrained tumor progression, promoted CD8 + T‐cell infiltration, decreased the regulatory T‐cell (Treg) fraction, and enriched M1 macrophages. Anti‐PD‐1 treatment further amplified the antitumor effect of CPAN. These results highlight a promising nanoprodrug‐based strategy for improving CRC immunotherapy by coordinated activation of ferroptosis and caspase‐independent pyroptosis.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: